Skip to content

Thymulin

A nine-amino-acid thymic hormone (pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is biologically inert until it binds a single zinc ion, discovered in Paris in the 1970s as Facteur Thymique Sérique and renamed thymulin in 1982 when the zinc dependence was proved. It drives T-cell maturation, falls with thymic involution, and is the most sensitive known marker of marginal zinc deficiency.

DEmergingModerate Data
Last updated 43 citations
TL;DR

Thymulin is the thymic hormone that does not work without zinc — strip the metal out and the same nine amino acids are inert, which is why it got a new name in 1982 when that was proved. Almost everything marketed about it inverts its actual evidence. It was tested in humans, but as Nonathymulin in the 1980s, in autoimmune disease rather than immune decline, at 5 mg a day — roughly ten to a hundred times what community protocols describe. It beat placebo in rheumatoid arthritis (56% versus 17% global improvement) and did nothing at all in multiple sclerosis. Development stopped there; no trial of injected thymulin has been registered anywhere since, and nothing has ever tested it for the age-related immune support it is now sold for. The best-evidenced way to raise thymulin activity in a person remains correcting a zinc deficiency. The genuinely new development is a 2026 Nature Communications paper identifying thymulin as a young-blood factor that quiets inflammation in aged myeloid cells and sensitises tumours to checkpoint therapy in mice.

What is Thymulin?

Thymulin is a nonapeptide — pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, sequenced from pig serum in 1977 — produced by thymic epithelial cells. Its defining property is that the peptide alone does nothing. Biological activity requires a single zinc ion bound at a 1:1 molar ratio; chelate the metal away and the identical amino-acid sequence is inert, which is why the zinc-bound form was given its own name, thymulin, in 1982, while the metal-free peptide kept the older name FTS. That dependence is not a footnote, it is the clinical story: zinc deficiency produces functional thymulin deficiency without any change in how much peptide the thymus makes, and correcting the zinc restores activity. Thymulin drives T-cell differentiation and maturation, and circulating levels fall with age as the thymus involutes — the observation behind every anti-aging claim made for it. What is usually left out is that exogenous thymulin has been tested in people, and not in the population the marketing implies. Synthetic thymulin reached controlled human trials in the 1980s as Nonathymulin, in rheumatoid arthritis and multiple sclerosis, at milligram doses. Development stopped after those trials and no thymulin product has ever been approved anywhere.

What Thymulin Is Investigated For

Thymulin is investigated for T-cell maturation support, age-related immune decline, zinc-dependent immune function, and anti-inflammatory applications — with more recent preclinical interest in neuropathic pain, asthma, multiple sclerosis, type 1 diabetes via thymulin-related peptides, and, most recently, cancer immunotherapy augmentation in aging (Kanemaru et al., Nature Communications 2026, showing thymulin as a young-host factor that restrains age-associated myeloid inflammation and enhances anti-PD-L1 response in aged tumor models). The strongest evidence is actually indirect: decades of biology from the Bach and Dardenne group establishing thymulin's essential role in T-cell differentiation and its zinc dependence, combined with clinical studies showing that zinc supplementation restores functional thymulin activity in several deficient populations (older adults, Crohn's disease, children with Down syndrome) — though a zinc trial in rural Gambian children found no in vivo thymulin effect, so the restoration is not universal. The honest caveats are substantial. Despite extensive basic immunology, thymulin has never been developed into an approved therapeutic. The human evidence for injecting exogenous synthetic thymulin is thin and decades old, and it is not what the wellness framing suggests: the controlled trials were in autoimmune disease, not immune deficiency. Two double-blind placebo-controlled trials in rheumatoid arthritis found 5 mg/day produced significant clinical improvement (56% versus 17% on placebo) with minimal adverse effects — but explicitly without clear changes in immunological parameters — while a randomized placebo-controlled trial in 40 patients with multiple sclerosis found no benefit at all. The best-evidenced clinical action for supporting thymulin biology is correcting zinc deficiency, not administering peptide; synthetic thymulin is biologically inactive without bound zinc, so injecting it into zinc-replete or zinc-deficient patients may produce different effects that no controlled human study has characterized. Research-chemical supply varies substantially in purity and identity.

T-cell maturation and immune function
Moderate70%
Anti-inflammatory effects
Emerging50%
Immune system restoration in aging
Emerging50%
Zinc-dependent immune support
Emerging50%
Early marker of marginal zinc deficiency — falls faster than plasma or lymphocyte zinc
Moderate70%
Young-blood factor restraining age-associated myeloid inflammation (2026, mice)
Preliminary30%

History & Discovery

Thymulin was identified and characterized in the 1970s by Jean-François Bach, Mireille Dardenne, and colleagues at the Necker Hospital and INSERM in Paris, who demonstrated a circulating thymic factor in mouse and human serum between 1972 and 1975, then went to pig serum in 1976 and 1977 for the material needed to isolate and sequence it — the order matters, because the hormone was found in mice and people first and purified from pigs second. Originally called Facteur Thymique Sérique (FTS), the molecule was isolated and purified from pig serum in 1977 and sequenced in the companion paper as pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn — nine residues, with a synthetic version reproducing the native activity — and was eventually shown to require a tightly bound zinc ion for that activity — without zinc, the same amino-acid sequence is essentially inert. This zinc dependency explained a long-standing clinical observation that zinc deficiency produces immune phenotypes resembling thymic atrophy. The name itself arrived in 1982. Dardenne, Pleau, Nabarra, Bach and colleagues showed in PNAS that stripping metal from FTS with a chelating agent abolished its activity, that zinc restored it at a 1:1 molar ratio, and that two distinct forms therefore existed — an inactive apo-peptide and an active zinc-bound one they proposed calling 'thymulin' (FTS-Zn). Synthetic thymulin did reach controlled human trials, a fact often lost in modern wellness framing of the peptide. Marketed as Nonathymulin, it was tested in autoimmune disease rather than immunodeficiency. Amor, Dougados, Dardenne and Bach ran two randomized double-blind placebo-controlled trials in rheumatoid arthritis (Ann Rheum Dis 1987) comparing 1, 5 and 10 mg/day; 5 mg/day produced significant global clinical improvement over placebo (56% vs 17%) with minimal adverse effects, though without clear accompanying changes in immunological parameters. Roullet and colleagues (Acta Neurol Scand 1989) then tested subcutaneous Nonathymulin against placebo in 40 patients with multiple sclerosis over six months and found no effect on disability scores, ambulation index, or functional scale. Development did not continue past these studies. Much of the subsequent thymulin biology was characterized by the Bach/Dardenne group across the 1970s through 1990s: the peptide's role in CD4/CD8 differentiation, its decline with age as the thymus involutes, its relationship to the hypothalamic-pituitary-thymic axis, and its modulation by other endocrine factors. Synthetic thymulin and thymulin-related peptides have been studied in animal models for inflammation, neuropathic pain, asthma, and infection. Despite this scientific depth, thymulin has not been developed into an approved therapeutic. There is no FDA-approved thymulin product, and the synthetic peptide that circulates in the wellness market is research-chemical material produced outside the regulated pharmaceutical supply chain. The clinical activity that matters most in modern practice — restoring thymulin function via correcting zinc deficiency — is achieved with zinc supplementation rather than with exogenous peptide.

How It Works

Thymulin is a tiny hormone your thymus makes to help train immune cells — T-cells — to work properly. The unusual thing about it is that it only works while holding onto a zinc atom. Without zinc the molecule is still there but does nothing, which is part of why zinc deficiency weakens immunity, and why thymulin activity drops faster than a blood zinc test does when zinc runs low. As you age the thymus shrinks and thymulin falls, which is the reason people connect it to immune aging. More recent work suggests a second job: thymulin seems to calm down inflammatory signalling in aging immune cells out in the body, not just in the thymus.

Thymulin binds to high-affinity receptors on T-cell precursors, promoting their differentiation into mature, functional T-cells. It modulates cytokine production, enhances NK cell activity, and influences the hypothalamic-pituitary-adrenal axis. The zinc-thymulin complex has been linked to nuclear protein kinase C signaling in T lymphocytes. A more strongly replicated mechanism is suppression of NF-kB signaling: Lunin and colleagues (IJMS 2019) reported that thymulin modulates NF-kB pathway activity through site-specific phosphorylation of RelA/p65 at Ser276 and Ser536 in an experimental autoimmune encephalomyelitis model, and the same NF-kB axis recurs in the sepsis and type 1 diabetes preclinical work cited below. That convergence is weaker than it looks, and worth stating plainly: the encephalomyelitis, sepsis and type 1 diabetes papers all come from the same Novoselova and Lunin laboratory at the Institute of Cell Biophysics in Pushchino, with largely the same author list, as do the blood-brain-barrier and extrathymic-production papers. Counting the independent 2026 myeloid work, this is two groups converging on NF-kB, not four. Kanemaru and colleagues (Nature Communications 2026) extended the mechanism beyond thymocyte biology by identifying thymulin as a heterochronic circulating factor that suppresses NF-κB-driven pro-inflammatory cytokine output in aged peripheral myeloid cells — a distinct peripheral inflammaging role that also enhances anti-PD-L1 checkpoint immunotherapy in aged tumor-bearing mice, adding a myeloid-axis dimension to the classical T-cell-maturation frame.

Evidence Snapshot

Overall Confidence50%

Human Clinical Evidence

Thin, old, and mixed — and not in the population the wellness framing implies. The controlled human trials of synthetic thymulin were in autoimmune disease: two double-blind placebo-controlled rheumatoid-arthritis trials found 5 mg/day clinically superior to placebo (56% vs 17% global improvement) with minimal adverse effects but no clear change in immunological parameters, and a randomized placebo-controlled trial in 40 patients with multiple sclerosis was negative. The separate human literature in elderly and zinc-deficient populations measures what zinc supplementation does to endogenous thymulin activity — it does not test exogenous thymulin administration. No modern trial of injected thymulin exists for any indication.

Animal / Preclinical

Extensive, and broader than the T-cell framing suggests — but concentrated in a small number of laboratories. Thymulin or its gene-therapy and nanoparticle formulations have shown anti-inflammatory and protective effects in rodent models of sepsis, type 1 diabetes, experimental autoimmune encephalomyelitis, allergic asthma, neuropathic and inflammatory pain, and blood-brain-barrier disruption, with NF-kB suppression recurring as the common mechanism. Most of that work comes from the Novoselova and Lunin group in Pushchino, so the apparent convergence across disease models reflects one programme rather than independent replication. The separate and genuinely independent 2026 Nature Communications work identifies thymulin as a circulating young-host factor that restrains inflammatory activation in aged myeloid cells and sensitises tumours to anti-PD-L1 therapy in aged mice.

Mechanistic Rationale

Strong for the classical biology, and unusually well-defined chemically: a sequenced nonapeptide, a proven 1:1 zinc requirement, a documented role in CD4/CD8 differentiation, and a clear relationship to thymic involution. The NF-kB arm is coherent and now reported at the level of specific RelA/p65 phosphorylation sites, but rests heavily on one laboratory. What the mechanism does not explain is the one positive human result: the 1987 rheumatoid-arthritis trials produced clinical improvement without clear change in immunological parameters.

Research Gaps & Open Questions

What the current literature has not yet settled about Thymulin:

  • 01Human pharmacokinetics of synthetic exogenous thymulin — absorption, distribution, half-life, and tissue uptake have not been characterized in humans for current research-chemical preparations.
  • 02Controlled human trials — most human evidence is decades old, small, in selected immunodeficient populations, and not directly applicable to current wellness use.
  • 03Translation of zinc-thymulin biology to therapeutic peptide use — restoring thymulin via zinc repletion is well evidenced; whether adding exogenous peptide to a zinc-replete patient produces additional clinical benefit is not.
  • 04Long-term safety — chronic immune modulation by exogenous thymulin has not been studied beyond short windows.
  • 05Quality and consistency of research-chemical supply — variation in purity, peptide identity, and endotoxin contamination across suppliers is not characterized for end users.
  • 06Synthetic analog development — thymulin-related peptides (PAT and others) have shown analgesic and anti-inflammatory effects in animal models; their human translational potential is largely unstudied.
  • 07Why the only positive human trial produced clinical improvement without a clear immunological signature. The 1987 rheumatoid-arthritis trials reported significant global improvement at 5 mg/day, plus improvement on four objective parameters, while stating the benefit was not accompanied by clear changes in immunological parameters. The picture is not quite as blank as that sounds — the same report notes a significant correlation between clinical response and T-cell subset imbalance measured with monoclonal antibodies and a functional suppressor T-cell assay — but what mediated the clinical effect was never established, and nobody has gone back to find out in the four decades since.
  • 08Whether the NF-kB suppression mechanism now reported across sepsis, type 1 diabetes, experimental autoimmune encephalomyelitis and aged myeloid cells is the unifying action of thymulin, and whether it is zinc-dependent in the same way the classical T-cell-maturation activity is.
  • 09Whether thymulin activity should be developed as a clinical zinc-status assay. It falls faster under zinc restriction than lymphocyte or plasma zinc, but no standardized, widely available assay exists, and no clinical decision thresholds have been established.

Forms & Administration

Thymulin is typically administered via subcutaneous or intramuscular injection. Zinc co-supplementation may be recommended to ensure biological activity. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

There is no established human therapeutic dose for exogenous thymulin. Animal studies have used widely varying microgram-range doses by intraperitoneal or subcutaneous routes; the actual controlled human trials used milligram doses in autoimmune disease, not microgram doses in immunodeficiency: two double-blind placebo-controlled trials of synthetic thymulin (marketed as Nonathymulin) in rheumatoid arthritis compared 1, 5, and 10 mg/day, with 5 mg/day the most effective (Amor, Dougados, Dardenne, Bach; Ann Rheum Dis 1987), and a 1989 multiple sclerosis trial used subcutaneous dosing over six months. Anyone extrapolating from historical human use should know those studies ran at milligram scale, roughly ten to a hundred times the figures circulating in community protocols. Research-chemical protocols circulating in the longevity community describe subcutaneous doses in the 100 mcg range, but these are extrapolations rather than evidence-based regimens.

Frequency

Animal protocols typically use daily or alternate-day dosing across short intervention windows. Endogenous thymulin shows a circadian rhythm with nocturnal peaks linked to melatonin signaling. There is no validated human cadence for exogenous administration.

Timing Considerations

No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.

Cycle Length

There is no recognized cycle. Animal studies have run from days to weeks. Long-term continuous use of exogenous thymulin in humans has not been studied.

Protocol Notes

The most evidence-based way to support thymulin biology in humans is to ensure adequate zinc status. Zinc deficiency reduces functional thymulin levels independently of peptide synthesis, and zinc repletion restores activity in deficient individuals — this has been shown in older adults and in Crohn's disease, and in children with Down syndrome. The evidence is not uniform: a zinc-supplementation trial in 110 young rural Gambian children found plasma thymulin varied strongly by clinic visit but reported no effect of zinc in vivo, and no significant benefit to T-cell numbers or ratios. Adding exogenous synthetic thymulin to zinc-replete patients has no human clinical trial base supporting benefit. Research-chemical thymulin varies in purity, identity verification, and endotoxin control. Even when correctly synthesized, the peptide is biologically inactive without bound zinc, so the practical pharmacology of injecting synthetic thymulin into a zinc-replete versus zinc-deficient patient may differ in ways that no controlled study has characterized.

Thymulin is not FDA-approved for any indication. The dosing description here reflects animal research and historical investigational use rather than a clinical recommendation.

Timeline of Effects

Onset

Endogenous thymulin acts on T-cell precursors over days to weeks during normal immune development. For exogenous administration, animal studies show measurable immune-parameter shifts within days of repeated dosing. There is no published human onset curve for the synthetic peptide as currently sold.

Peak Effect

In animal models, peak immunological effects from repeated thymulin dosing typically emerge over 1–4 weeks. Human anecdotal reports vary widely and are not supported by controlled data.

After Discontinuation

Thymulin has a short circulating half-life. Effects on T-cell populations and cytokine signaling would be expected to fade over days to weeks once dosing stops. The deeper question — whether exogenous thymulin produces durable changes to thymic function in adults — has not been answered in humans.

Monitoring & Measurement

Bloodwork & Labs

  • •CBC with differential — total lymphocytes and CD4 / CD8 subsets
  • •Serum zinc — thymulin is zinc-dependent, and zinc insufficiency is the single factor most likely to blunt any response
  • •hs-CRP
  • •Quantitative immunoglobulins (IgG, IgA, IgM)

Functional & Performance Tests

  • •Structured illness frequency and duration diary

When to Test

Baseline, 12 weeks, and 24 weeks.

Interpretation & Notes

Thymulin's biological activity is zinc-dependent — this is the unusual, mechanism-specific measurement point for this peptide. A low or borderline serum zinc at baseline is a likely reason for non-response, and checking it is both cheap and genuinely informative. Otherwise the measurement setup is the same as the other thymic peptides: CBC with differential plus a structured infection diary, assessed over 3–6 months. Thymulin has no approved therapeutic use and limited Western clinical data, so the honesty of an n-of-1 diary plus basic immune labs matters more than trying to extract signal from specialty panels. Labs via LabCorp, Quest, Marek Health, or Ulta Lab Tests.

Common Questions

Why does Thymulin need zinc?

Thymulin is biologically inactive without zinc. The zinc ion is essential for the peptide to adopt its active conformation and bind to its receptors on T-cells. This is why zinc deficiency can impair thymulin function.

Has thymulin ever been tested in humans?

Yes, but a long time ago and in a different population than most people assume. Synthetic thymulin was developed as Nonathymulin and tested in autoimmune disease, not immune deficiency. Two randomized double-blind placebo-controlled trials in rheumatoid arthritis (Ann Rheum Dis 1987) compared 1, 5, and 10 mg/day; the 5 mg dose produced significant global clinical improvement over placebo — 56% versus 17% — with minimal adverse effects, though the authors noted the benefit came without clear changes in immunological parameters. A randomized placebo-controlled trial in 40 patients with multiple sclerosis (Acta Neurol Scand 1989) was negative on every disability measure. Two things follow. First, the human doses were milligrams per day, roughly ten to a hundred times what community protocols describe. Second, development stopped there — no modern trial of injected thymulin exists for any indication, and nothing has tested it for the age-related immune support it is now marketed for.

Is thymulin a better zinc-status marker than a serum zinc test?

It appears to be more sensitive, which is a genuinely useful thing to know even if you never consider taking the peptide. Serum zinc is a notoriously lagging and insensitive indicator. Two separate lines of evidence say so, and they are worth keeping apart. In Prasad's experimental human zinc-restriction model, thymulin activity fell within 8 to 12 weeks of a zinc-deficient diet, while lymphocyte zinc took about 20 weeks and plasma zinc about 24 weeks to drop (PMID 32411807). Separately, a 2021 comparison in Biological Trace Element Research — a rat study, not a human one — found serum thymulin activity 61% lower against a 31% fall in serum zinc, and reported thymulin as more sensitive to restricted zinc intake than the four other measures tested (serum zinc, serum extracellular superoxide dismutase, serum 5'-nucleotidase and liver metallothionein). The practical implication is the opposite of the usual peptide pitch: the interesting thing about thymulin for most people is as a readout of zinc status, not as something to inject. Thymulin activity assays are not routinely available in commercial labs, so this remains more useful as a reason to take a borderline serum zinc seriously than as a test to order.

What does the 2026 Nature Communications paper actually show?

It is the most interesting thing published about thymulin in decades, and it is entirely in mice. Kanemaru and colleagues used heterochronic parabiosis — surgically joining the circulations of a young and an old animal — along with bone-marrow chimeras, and found that the inflammatory activation seen in aged myeloid cells is suppressed by circulating factors present in young hosts that do not come from bone marrow. Screening for what those factors were identified thymulin, acting by inhibiting NF-kB signalling and so damping pro-inflammatory cytokine production. They then showed thymulin improved antitumour T-cell immunity, tumour control and survival, and sensitised tumours to anti-PD-L1 checkpoint therapy, in an age-dependent way. Two caveats worth holding onto. First, this is a peripheral myeloid mechanism, which is a different job from the classical thymic T-cell maturation story, not a confirmation of it. Second, nothing here is a human result or a dosing protocol — the inflammatory phenotype was documented in aged humans as well as mice, but the thymulin intervention was mouse-only. It is a reason to take the molecule seriously again, not a reason to inject it.

Has anyone registered a thymulin trial recently?

No. Searches of ClinicalTrials.gov, the EU Clinical Trials Register and the EU CTIS return no interventional trial of thymulin or Nonathymulin under any of its names — thymulin, nonathymulin, FTS-Zn or serum thymic factor. The single ClinicalTrials.gov record that mentions thymulin is a 2011 zinc-and-polio-vaccine study in Pakistani infants where thymulin appears only in the background rationale, not as an intervention or an outcome. This is partly an artefact of timing, since the 1987 and 1989 trials predate ClinicalTrials.gov by more than a decade, but the conclusion holds either way: no modern clinical development programme for thymulin exists anywhere that is publicly searchable.

How does Thymulin differ from Thymosin Alpha-1?

Both are thymic peptides but have different structures and mechanisms. Thymulin is zinc-dependent and primarily involved in T-cell maturation, while Thymosin Alpha-1 has broader immunomodulatory effects and a more developed clinical record — it holds FDA orphan-drug designation and is approved in a number of other countries, but it is not FDA-approved for any indication.

Who Thymulin Is NOT For

Contraindications
  • •Active autoimmune disease — exogenous immune-modulating peptides are theoretically capable of exacerbating autoimmune activity. The nuance here is real: the only controlled human trials of synthetic thymulin were in rheumatoid arthritis and multiple sclerosis, and reported minimal adverse effects, so the historical record is not one of harm in autoimmunity. But those trials used a pharmaceutical-grade product at defined milligram doses under monitoring, which is not what self-administration of research-chemical thymulin involves, and they are nearly forty years old.
  • •Active or recent organ transplantation requiring immunosuppression — interference with the carefully managed immune state is a real concern and unstudied.
  • •Pregnancy and breastfeeding — no reproductive safety data; thymic and immune-development effects on the fetus and neonate are unknown.
  • •Pediatric use — no studies in pediatric populations of synthetic exogenous thymulin.
  • •Known hypersensitivity to peptide therapeutics or to excipients in research-chemical preparations of unknown purity.
  • •Use of unverified research-chemical thymulin in any clinical context — purity, identity, and endotoxin status are not assured outside regulated supply chains.

Drug & Supplement Interactions

There is no published human drug-interaction data for synthetic exogenous thymulin. The following are theoretical and based on mechanism. The most consistent practical interaction is with zinc status. Thymulin requires bound zinc to be biologically active. Zinc-deficient patients may respond differently to exogenous thymulin than zinc-replete patients. Zinc supplementation independently raises functional thymulin activity, which is part of why correcting zinc deficiency is the better-evidenced clinical action than injecting peptide. Immunosuppressive medications (corticosteroids, calcineurin inhibitors, mTOR inhibitors, biologics targeting T-cell pathways) may have unpredictable interactions with an immune-modulating peptide whose human pharmacology is uncharacterized. Co-administration is not advised outside a controlled investigational setting. Melatonin and the broader neuroendocrine system interact with endogenous thymulin secretion (nocturnal peaks have been linked to melatonin), and other thymic peptides (thymosin alpha-1 in particular) act through partially overlapping pathways. How exogenous synthetic thymulin layers on top of these endogenous rhythms in any specific patient is not characterized.

Safety Profile

Safety Information

Common Side Effects

Generally well-tolerated in the historical controlled trials — the rheumatoid-arthritis trials reported minimal adverse effects and the multiple-sclerosis trial recorded no significant side effects, at milligram doses of a pharmaceutical-grade productMild immune activation symptoms

Cautions

  • • Requires adequate zinc status
  • • Not widely available commercially
  • • Limited standardized formulations

What We Don't Know

Optimal dosing, zinc co-supplementation requirements, and long-term effects of exogenous thymulin are not well-established.

Myths & Misconceptions

Myth

Injecting thymulin restores a youthful immune system.

Reality

Endogenous thymulin declines with thymic involution, but exogenous synthetic thymulin has not been shown to restore thymic function or broad immune competence in adults. The human evidence base for using injected thymulin as an anti-aging immune therapy is not there.

Myth

Thymulin works the same with or without zinc.

Reality

Thymulin is biologically inactive without bound zinc. Restoring zinc status in deficient individuals raises functional thymulin activity. Injecting synthetic thymulin into a zinc-deficient patient cannot reproduce normal physiology if the metal cofactor is missing.

Myth

Because thymulin is endogenous, exogenous synthetic thymulin is automatically safe.

Reality

Endogenous regulation involves tight neuroendocrine and circadian control. Subcutaneously injected synthetic peptide bypasses that regulation. Safety of chronic exogenous administration has not been characterized in humans, and research-chemical supply quality is highly variable.

Myth

Thymulin has been shown to work in humans, so injecting it is evidence-based.

Reality

Thymulin has human trial data, but almost never the data people think. The controlled trials were of synthetic thymulin as Nonathymulin, in the 1980s, in autoimmune disease — rheumatoid arthritis, where 5 mg/day beat placebo on global improvement 56% to 17%, and multiple sclerosis, where it did nothing on any endpoint. Nobody has tested it for immune aging, immune restoration, infection resistance or longevity. The doses were milligrams per day of a pharmaceutical-grade product under monitoring, roughly ten to a hundred times the microgram figures in community protocols, and the studies are nearly forty years old. Citing the rheumatoid-arthritis result as support for an anti-aging injection protocol is citing the wrong disease, the wrong population and the wrong dose.

Myth

Multiple independent labs have confirmed thymulin's anti-inflammatory mechanism.

Reality

The NF-kB suppression finding is real and reported across sepsis, type 1 diabetes, experimental autoimmune encephalomyelitis and blood-brain-barrier models — but those papers share an author list. They come from the Novoselova and Lunin laboratory at the Institute of Cell Biophysics in Pushchino, so what looks like convergence across four disease models is one research programme applying the same hypothesis repeatedly. The genuinely independent corroboration is the 2026 Nature Communications work on aged myeloid cells, which found NF-kB inhibition by a different route in a different system. Two groups, not several — enough to be interesting, not enough to call replicated.

Myth

Thymulin and Thymosin Alpha-1 are interchangeable.

Reality

They are distinct peptides with different structures, mechanisms, and clinical histories. Thymosin alpha-1 has orphan-drug status and a more developed clinical record in specific infectious-disease and immunologic indications. Thymulin is a zinc-dependent nonapeptide with no approved therapeutic use.

Published Research

43 studies

Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy

Kanemaru et al., Nature Communications 21 July 2026. Identifies thymulin as a circulating young-host factor that suppresses pro-inflammatory NF-κB signaling in aged myeloid cells and enhances the anti-tumor response to anti-PD-L1 checkpoint blockade in aged tumor-bearing mice — the highest-tier journal thymulin has appeared in for years, and the paper that opens an immuno-oncology angle beyond the classical T-cell-maturation frame. Positions thymulin as a heterochronic-parabiosis-relevant factor in the aging-inflammation-cancer axis.

PreclinicalPMID: 42481458

Protective effect of exogenous peroxiredoxin 6 and thymic peptide thymulin on BBB conditions in an experimental model of multiple sclerosis

PreclinicalPMID: 37633587

Thymus-derived hormonal and cellular control of cancer

ReviewPMID: 37529610

Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice

PreclinicalPMID: 33779346

Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma

PreclinicalPMID: 32577505

Lessons Learned from Experimental Human Model of Zinc Deficiency

Prasad, Journal of Immunology Research 2020 — the human source for the zinc-restriction timeline this page quotes, from the researcher who defined human zinc deficiency as a clinical entity. In volunteers placed on a zinc-deficient diet, thymulin activity and IL-2 mRNA fell within 8 to 12 weeks, while lymphocyte zinc took about 20 weeks and plasma zinc about 24 weeks to decline. That ordering is the whole argument for thymulin as an early marker of marginal zinc status, and it is human data rather than the rat comparison usually cited alongside it.

ReviewPMID: 32411807

Comparison of Thymulin Activity with Other Measures of Marginal Zinc Deficiency

DiSilvestro and colleagues, Biological Trace Element Research 2021 — the source of the 61% figure that circulates in human terms and is in fact a rat study. Rats fed 5 versus 25 ppm zinc showed serum thymulin activity 61% lower against a 31% fall in serum zinc, making thymulin more sensitive to restricted intake than the four other measures tested. Note that Mireille Dardenne is a co-author, so this is not an independent check on the Paris group's own marker.

PreclinicalPMID: 32363520

Protective Effect of PBCA Nanoparticles Loaded with Thymulin Against the Relapsing-Remitting Form of Experimental Autoimmune Encephalomyelitis in Mice

Lunin and colleagues, International Journal of Molecular Sciences 2019 — the source for the specific NF-kB mechanism this page describes, in a relapsing-remitting EAE model in mice: thymulin modulated NF-kB pathway activity via site-specific phosphorylation of RelA/p65 at Ser276 and Ser536. The most molecularly precise mechanistic claim available for thymulin, and the anchor of the Pushchino group's wider programme across sepsis, type 1 diabetes and blood-brain-barrier models.

PreclinicalPMID: 31671728

Prenatal and childhood exposures are associated with thymulin concentrations in young adolescent children in rural Nepal

Randomized Controlled TrialPMID: 31475652

Thymulin treatment attenuates inflammatory pain by modulating spinal cellular and molecular signaling pathways

PreclinicalPMID: 30851702

Targeting inflammatory components in neuropathic pain: The analgesic effect of thymulin related peptide

ReviewPMID: 30503917

Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation

PreclinicalPMID: 29795607

A new adenovector system for implementing thymulin gene therapy for inflammatory disorders

PreclinicalPMID: 28501652

Extrathymic production of thymulin induced by oxidative stress, heat shock, apoptosis, or necrosis

PreclinicalPMID: 28281875

Effects of zinc-fortified drinking skim milk (as functional food) on cytokine release and thymic hormone activity in very old persons: a pilot study

Randomized Controlled TrialPMID: 24771015

Physiology and therapeutic potential of the thymic peptide thymulin

ReviewPMID: 24588820

Targeting neuroinflammation for therapeutic intervention in neurodegenerative pathologies: a role for the peptide analogue of thymulin (PAT)

ReviewPMID: 22861065

Immunomodulatory role of thymulin in lung diseases

ReviewPMID: 20055713

The thymus-neuroendocrine axis: physiology, molecular biology, and therapeutic potential of the thymic peptide thymulin

ReviewPMID: 19236333

Role of thymulin or its analogue as a new analgesic molecule

ReviewPMID: 17192563

Peripheral and mesencephalic transfer of a synthetic gene for the thymic peptide thymulin

Comparative StudyPMID: 16716832

Thymulin and the neuroendocrine system

ReviewPMID: 15003367

Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide in the rat

Comparative StudyPMID: 12110619

Melatonin is responsible for the nocturnal increase observed in serum and thymus of thymosin alpha1 and thymulin concentrations: observations in rats and humans

Clinical TrialPMID: 10696913

Cytokine-mediated or direct effects of thymulin on the nervous system as assessed by pain-related behavior

ReviewPMID: 9876233

Benefit of oral zinc supplementation as an adjunct to zidovudine (AZT) therapy against opportunistic infections in AIDS

Randomized Controlled TrialPMID: 8582783

A trial of zinc supplementation in young rural Gambian children

Clinical TrialPMID: 8457531

Zinc supplementation restores plasma concentrations of zinc and thymulin in patients with Crohn's disease

Randomized Controlled TrialPMID: 8364132

Effects of growth hormone and thyroxine on thymulin secretion in aging rats

Comparative StudyPMID: 8255394

Modulation of the neuroendocrine system and immune functions by zinc supplementation in children with Down's syndrome

Clinical TrialPMID: 8019155

Biochemical and biological aspects of the interaction between thymulin and zinc

ReviewPMID: 7681212

Generation of a monoclonal antibody against facteur thymique serique (FTS)

Comparative StudyPMID: 7044627

Contribution of zinc and other metals to the biological activity of the serum thymic factor

Dardenne, Pleau, Nabarra, Lefrancier, Derrien, Choay and Bach, PNAS 1982. The paper that named the molecule. Showed that chelating metal from the serum thymic factor abolishes its activity, that zinc restores it at a 1:1 molar ratio, and that two forms therefore exist — an inactive zinc-free peptide and an active zinc-bound one, for which the authors proposed the name 'thymulin' (FTS-Zn). The origin of both the name and the zinc-dependence that defines this peptide.

PreclinicalPMID: 6957870

Relationship between a spleen-derived immunosuppressive peptide 'SDIP' and the 'Facteur thymique sérique' (FTS): biochemical and biological comparison of the two factors

Comparative StudyPMID: 6682089

Studies on the zinc binding site to the serum thymic factor

PreclinicalPMID: 6538097

New insight into lymphocytic chalone research. The 'facteur thymique Sérique' might be responsible for part of the immunosuppressive activity detected in the 'chalone fraction'

Comparative StudyPMID: 6212552

Studies on thymus products. II. Demonstration and characterization of a circulating thymic hormone.

Bach and Dardenne, Immunology 1973 — the paper that put the serum thymic factor on the map, following their 1972 note in Annales de l'Institut Pasteur. Everything on this page descends from this programme at the Hopital Necker and INSERM: the demonstration that serum contains a thymus-derived factor capable of conferring T-cell markers, the assay that made it measurable, and the name Facteur Thymique Serique that the peptide carried for the next decade.

PreclinicalPMID: 4542646

Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials

Amor, Dougados, Mery, Dardenne, and Bach, Annals of the Rheumatic Diseases 1987. The only positive controlled human trial of synthetic thymulin: two randomized double-blind placebo-controlled trials in rheumatoid arthritis comparing 1, 5, and 10 mg/day, with 5 mg/day producing significant global clinical improvement (56% vs 17% on placebo) and minimal adverse effects — but, notably, without clear changes in immunological parameters. The reference point for what exogenous thymulin has actually been shown to do in people, and at what dose.

Randomized Controlled TrialPMID: 3310925

Serum thymulin in human zinc deficiency

Clinical TrialPMID: 3262625

Thymulin, a zinc-dependent hormone

ReviewPMID: 2657247

Nonathymulin treatment of multiple sclerosis: double-blind pilot study

Roullet and colleagues, Acta Neurologica Scandinavica 1989 — the negative half of thymulin's human record, and the reason the rheumatoid-arthritis result should not be generalised. Forty matched patients with evolving multiple sclerosis and moderate disability received subcutaneous Nonathymulin or placebo for six months and were followed for a further six. There was no significant difference on any endpoint: Kurtzke Disability score, Ambulation Index or Functional Scale. The authors describe it as a pilot study. No controlled trial of injected thymulin has been published in any indication since.

Randomized Controlled TrialPMID: 2618585

Structural study of circulating thymic factor: a peptide isolated from pig serum. II. Amino acid sequence.

Pleau, Dardenne, Blouquit and Bach, Journal of Biological Chemistry 1977 — the sequence, and the source for the nine residues this page quotes. FTS from pig serum was established by Edman degradation as pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, and a synthetic version showed the same biological activities as the native peptide. The N-terminal glutamine cyclises to pyroglutamate, which is why the sequence is written with a pyroGlu rather than a Gln.

PreclinicalPMID: 914862

Structural study of circulating thymic factor: a peptide isolated from pig serum. I. Isolation and purification.

PreclinicalPMID: 303241

Quick Facts

Class
Thymic Peptide
Tier
D
Evidence
Emerging
Safety
Moderate Data
Updated
Nov 2026
Citations
43PubMed

Also known as

Facteur Thymique SeriqueFTSZinc-Thymulin

Tags

Immune SupportAnti-InflammatoryThymicZinc-Dependent

Conditions Discussed

Evidence Score

Overall Confidence50%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.